JP2004527213A5 - - Google Patents

Download PDF

Info

Publication number
JP2004527213A5
JP2004527213A5 JP2002518253A JP2002518253A JP2004527213A5 JP 2004527213 A5 JP2004527213 A5 JP 2004527213A5 JP 2002518253 A JP2002518253 A JP 2002518253A JP 2002518253 A JP2002518253 A JP 2002518253A JP 2004527213 A5 JP2004527213 A5 JP 2004527213A5
Authority
JP
Japan
Prior art keywords
polypeptide
nucleic acid
acid molecule
antigen
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002518253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004527213A (ja
JP5087201B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/024134 external-priority patent/WO2002012281A2/en
Publication of JP2004527213A publication Critical patent/JP2004527213A/ja
Publication of JP2004527213A5 publication Critical patent/JP2004527213A5/ja
Application granted granted Critical
Publication of JP5087201B2 publication Critical patent/JP5087201B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002518253A 2000-08-03 2001-08-02 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン Expired - Lifetime JP5087201B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22290200P 2000-08-03 2000-08-03
US60/222,902 2000-08-03
PCT/US2001/024134 WO2002012281A2 (en) 2000-08-03 2001-08-02 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008197856A Division JP2009017883A (ja) 2000-08-03 2008-07-31 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン

Publications (3)

Publication Number Publication Date
JP2004527213A JP2004527213A (ja) 2004-09-09
JP2004527213A5 true JP2004527213A5 (enExample) 2008-09-18
JP5087201B2 JP5087201B2 (ja) 2012-12-05

Family

ID=22834209

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002518253A Expired - Lifetime JP5087201B2 (ja) 2000-08-03 2001-08-02 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン
JP2008197856A Pending JP2009017883A (ja) 2000-08-03 2008-07-31 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008197856A Pending JP2009017883A (ja) 2000-08-03 2008-07-31 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン

Country Status (8)

Country Link
US (3) US7342002B2 (enExample)
EP (1) EP1363938B1 (enExample)
JP (2) JP5087201B2 (enExample)
AU (1) AU2001278117A1 (enExample)
CA (1) CA2417214C (enExample)
DK (1) DK1363938T3 (enExample)
ES (1) ES2454640T3 (enExample)
WO (1) WO2002012281A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
AU2001290520A1 (en) * 2000-08-01 2002-02-13 The Johns Hokpins University Intercellular transport protein linked to an antigen as a molecular vaccine
WO2002012281A2 (en) 2000-08-03 2002-02-14 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
AU2002242016A1 (en) 2001-02-01 2002-08-12 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
US20070026501A1 (en) * 2003-04-18 2007-02-01 Joe Chiba Immunogen, composition for immulogical use and process for producing antibody using the same
US9701725B2 (en) * 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
ES2427641T3 (es) 2003-05-22 2013-10-31 Ibio, Inc. Molécula vehículo recombinante para la expresión, el suministro y la purificación de polipéptidos diana
WO2005081716A2 (en) * 2003-11-24 2005-09-09 The Johns Hopkins University DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
AU2003290460A1 (en) * 2003-12-24 2005-07-14 Leiden University Medical Center Synthetic protein as tumor-specific vaccine
CA2583361C (en) 2004-10-15 2015-08-04 Sekisui Chemical Co., Ltd. Gene immunization using an antigen-chaperonin fusion
AU2005322960A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
EP1846026A4 (en) * 2005-01-26 2008-07-02 Univ Johns Hopkins ANTIBODY DNA VACCINE WITH PLASMIDES FOR CODING A MUTATED ONCOPROTEIN ANTIGEN AND CALRETICULIN
WO2007117264A2 (en) * 2005-08-03 2007-10-18 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
CN101395174B (zh) * 2006-02-13 2014-03-19 艾比欧公司 人类乳头瘤病毒（hpv）抗原、疫苗组合物和相关方法
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
WO2008024844A2 (en) * 2006-08-22 2008-02-28 The Johns Hopkins University Anticancer combination therapies
WO2008046251A1 (fr) * 2006-10-19 2008-04-24 Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. Protéines hybrides contenant un domaine n de la calréticuline humaine et des protéines e6 ou e7 du papillomavirus humain de type 16, et utilisations associées
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
US20100291683A1 (en) * 2007-03-27 2010-11-18 Lung-Ji Chang Modified Antigen Presenting Cells and Methods of Use
WO2009009759A2 (en) * 2007-07-11 2009-01-15 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
KR20110011595A (ko) * 2008-01-28 2011-02-08 탭이뮨, 인크. 면역 반응 증진을 위한 타파신 증대
EP2752193B1 (en) 2008-03-03 2017-01-11 The University of Miami Allogeneic cancer cell-based immunotherapy
WO2009117116A2 (en) 2008-03-20 2009-09-24 University Of Miami Heat shock protein gp96 vaccination and methods of using same
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
WO2010030861A2 (en) * 2008-09-11 2010-03-18 Calretex, Llc Compositions and methods for purifying calreticulin
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
CA2776144C (en) 2009-09-29 2020-10-27 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
PL2591114T3 (pl) * 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
KR20140045341A (ko) * 2011-02-23 2014-04-16 유니버시티 오브 마이애미 Siv/hiv로부터의 보호를 위한 조합된 세포 기반의 gp96-ig-siv/hiv, 재조합 gp120 단백질 백신접종
LT3892295T (lt) 2011-05-24 2023-07-10 BioNTech SE Individualizuotos vakcinos nuo vėžio
EP2752112B1 (en) * 2011-09-02 2016-04-27 Kaneka Corporation Transgenic bird expressing foreign gene using endoplasmic reticulum chaperone promoter
WO2013093629A2 (en) * 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
JP6484558B2 (ja) 2012-11-28 2019-03-13 バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ 癌ワクチンの組み合せ物
WO2014164727A1 (en) * 2013-03-12 2014-10-09 Wisconsin Alumni Research Foundation A method of treating fungal infection
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017155981A1 (en) * 2016-03-07 2017-09-14 Massachusetts Institute Of Technology Protein-chaperoned t-cell vaccines
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
SG11201911430PA (en) 2017-07-04 2020-01-30 Curevac Ag Novel nucleic acid molecules
CN109182339A (zh) * 2018-09-06 2019-01-11 青岛农业大学 一种许氏平鮋钙网蛋白基因及应用
CA3161800A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744133A (en) * 1986-08-13 1998-04-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor
US4898730A (en) * 1987-03-13 1990-02-06 The University Of British Columbia Method to stimulate the immune response to specific antigens
US5582831A (en) * 1991-11-26 1996-12-10 Yeda Research And Development Co., Ltd. Anti-tumor vaccines
DE68924162T2 (de) 1988-06-15 1996-04-25 Medical Res Council Stressproteine und verwendungen dafür.
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
DE3907721A1 (de) * 1989-03-10 1990-09-20 Behringwerke Ag Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5821088A (en) * 1990-05-11 1998-10-13 Siga Pharmaceuticals, Inc. Use of gram-positive bacteria to express recombinant proteins
CN1067382A (zh) 1990-09-26 1992-12-30 布里斯托尔-迈尔斯斯奎尔公司 人类乳头状瘤病毒肽的表达以及在致免疫组合物中的应用
US5674486A (en) * 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
ATE234860T1 (de) * 1991-07-13 2003-04-15 Dade Behring Marburg Gmbh Verwendung von hpv-16 e6 und e7-gen gewonnen peptiden für den diagnostischen zweck
GB9207701D0 (en) 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
IL106760A (en) 1992-08-25 1999-12-31 Miles Inc Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5997869A (en) * 1993-03-15 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Peptides containing a fusion joint of a chimeric protein encoded by DNA spanning a tumor-associated chromosomal translocation and their use as immunogens
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
US5426097A (en) * 1993-04-06 1995-06-20 The Trustees Of Columbia University In The City Of New York Calreticulin: a novel antithrombotic agent
ES2171454T3 (es) 1993-06-04 2002-09-16 Whitehead Biomedical Inst Proteinas de estres y sus usos.
US5646008A (en) 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5591716A (en) * 1993-11-19 1997-01-07 New York University Beneficial wound healing applications of calreticulin and other hyaluronan-associated proteins
EP0659438A1 (en) 1993-12-23 1995-06-28 Boehringer Mannheim Gmbh Conjugates consisting of peptidic T cell antigens and cell binding groups, and their use for therapy
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
US5854202A (en) 1995-01-24 1998-12-29 Dedhar; Shoukat Peptide fragments of calreticulin, peptide mimetics thereof, and pharmaceutical compostions comprising same
AU5512096A (en) 1995-05-17 1996-11-29 University Of Alberta Method of inhibiting restenosis using calreticulin
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
AU6504596A (en) 1995-07-21 1997-02-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
CA2229543A1 (en) 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
DE19534348C2 (de) 1995-09-15 1997-07-10 Wieland Heinrich Prof Dr Med Verfahren zur Bestimmung von Autoimmunphänomenen
WO1997020854A1 (en) * 1995-12-05 1997-06-12 University Of Massachusetts Recombinant gas vesicles and uses thereof
BR9708387A (pt) * 1996-03-28 2000-01-04 Genitrix Llc Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
AU738649B2 (en) 1996-04-26 2001-09-20 Rijksuniversiteit Te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
US5951975A (en) * 1996-06-28 1999-09-14 University Of Pittsburgh Induction of CTLs specific for natural antigens by cross priming immunization
CA2265935C (en) * 1996-09-20 2006-09-05 The University Of New Mexico Heat shock protein complexes
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
EP0941315B1 (en) 1996-11-26 2006-03-01 Stressgen Biotechnologies Corporation Fusion proteins containing stress proteins for inducing immune responses
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
US6017735A (en) 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
AU7022898A (en) 1997-04-23 1998-11-13 Ontario Cancer Treatment & Research Foundation Calreticulin-deficient cells
US6319503B1 (en) 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
HUP0003601A3 (en) 1997-08-05 2003-03-28 Stressgen Biotechnologies Corp Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins
AU3910097A (en) 1997-08-05 1999-03-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Live recombinant vaccine comprising inefficiently or non-replicating vir us
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US6331388B1 (en) * 1997-10-17 2001-12-18 Wisconsin Alumni Research Foundation Immune response enhancer
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US6534482B1 (en) 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
EP1086129A1 (en) 1998-06-17 2001-03-28 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and methods of use thereof
US6235523B1 (en) * 1998-09-04 2001-05-22 Connaught Laboratories Limited Vectors for DNA immunization against cervical cancer
US7001995B1 (en) * 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
CN1411512A (zh) 1999-10-20 2003-04-16 约翰霍普金斯大学医学院 嵌合的免疫原性组合物及其编码核酸
US6734173B1 (en) * 1999-10-20 2004-05-11 Johns Hopkins University HSP DNA vaccines
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US20010034042A1 (en) * 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
US6967075B2 (en) * 2000-04-07 2005-11-22 Schering Corporation HCV replicase complexes
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
SK18362002A3 (sk) 2000-06-26 2004-02-03 Stressgen Biotechnologies Corporation Použitie prostriedku s obsahom fúzneho proteínu
AU2001290520A1 (en) * 2000-08-01 2002-02-13 The Johns Hokpins University Intercellular transport protein linked to an antigen as a molecular vaccine
WO2002012281A2 (en) 2000-08-03 2002-02-14 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
JP3930243B2 (ja) * 2000-11-06 2007-06-13 本田技研工業株式会社 マグネットポンプ
CZ302719B6 (cs) * 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
AU2002242016A1 (en) * 2001-02-01 2002-08-12 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
WO2002074920A2 (en) 2001-03-16 2002-09-26 Johns Hopkins University A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
US20030144221A1 (en) 2001-07-17 2003-07-31 Isis Pharmaceuticals Inc. Antisense modulation of BCL2-associated X protein expression
CN100335121C (zh) * 2001-07-20 2007-09-05 得克萨斯大学体系董事会 涉及hpv相关的癌前期的和癌的生长(包括cin)的方法和组合物
US20060040262A1 (en) 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
AU2003224732A1 (en) 2002-03-25 2003-10-13 The Trustees Of Boston University Method of using anti-apoptotic factors in gene expression
DK1553966T3 (da) 2002-10-03 2012-09-17 Wyeth Corp Fusionspeptider omfattende human papillomavirus E7- og E6- polypeptider samt immunogene sammensætninger deraf
US20070026076A1 (en) * 2003-02-24 2007-02-01 Tzyy-Choou Wu Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
US9701725B2 (en) 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2005081716A2 (en) 2003-11-24 2005-09-09 The Johns Hopkins University DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
AU2005322960A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
EP1846026A4 (en) 2005-01-26 2008-07-02 Univ Johns Hopkins ANTIBODY DNA VACCINE WITH PLASMIDES FOR CODING A MUTATED ONCOPROTEIN ANTIGEN AND CALRETICULIN

Similar Documents

Publication Publication Date Title
JP2004527213A5 (enExample)
EP1222289B1 (en) Chimeric immunogenic compositions and nucleic acids encoding them
CN100590131C (zh) 用于将蛋白定向到胞外体的方法和化合物
AU2017297610B2 (en) Compositions and methods for alphavirus vaccination
CN103415620B (zh) 诱导针对EGFRvIII的免疫应答的方法和组合物
AU768807B2 (en) Ordered molecular presentation of antigens, method of preparation and use
EP1363938B1 (en) Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
AU692152B2 (en) Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
JP5788676B2 (ja) デングウイルスの複数のサブタイプに対する新規ワクチン
JP4713809B2 (ja) Ｂ型肝炎コア抗原融合タンパク質
US7994283B2 (en) Dimeric proteins for immunization
KR20020068040A (ko) 키메라 면역원성 조성물 및 그들을 암호화하는 핵산
EP1644048B1 (en) Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
Rush et al. Efficient priming of CD4+ and CD8+ T cells by DNA vaccination depends on appropriate targeting of sufficient levels of immunologically relevant antigen to appropriate processing pathways
JP2022046617A (ja) 異種ポリペプチドを含むＣｙａＡベースのキメラタンパク質及び免疫応答の誘導におけるその使用
KR20200027956A (ko) 키메라 바이러스-유사 입자 및 면역 반응의 항원-특이적 재지향자로서의 이의 용도
US20120328640A1 (en) Methods and compositions for the treatment and prevention of cancer
JP7686302B2 (ja) 融合遺伝子、組換え新型コロナウイルス高効率免疫ｄｎａワクチン、それらの構築方法及び使用
Fissolo Priming polyvalent immunity by DNA vaccines expressing chimeric antigens with a stress protein-capturing, viral J-domain
JP4837219B2 (ja) 融合タンパク質に対する免疫応答に関する物質および方法
US6562800B1 (en) Use of immunopotentiating sequences for inducing immune response
Dakappagari et al. Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T‐cell responses in HLA‐A* 201 mice
JP2005524719A (ja) 免疫応答を誘導するための方法および組成物
JP5901084B2 (ja) ペプチドアジュバント
Gu et al. Targeting hepatitis B virus antigens to dendritic cells by heat shock protein to improve DNA vaccine potency